Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
20.74
-0.75 (-3.49%)
At close: Apr 29, 2026, 4:00 PM EDT
20.60
-0.14 (-0.68%)
After-hours: Apr 29, 2026, 4:10 PM EDT

Lyell Immunopharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2019
Net Income
-274.45-342.99-234.63-183.12-250.22
Upgrade
Depreciation & Amortization
11.5419.6320.2518.0213.62
Upgrade
Loss (Gain) From Sale of Assets
3.341.341.510.11.21
Upgrade
Asset Writedown & Restructuring Costs
67.78138.48---
Upgrade
Loss (Gain) From Sale of Investments
14.26-1.713.331.1538.35
Upgrade
Stock-Based Compensation
41.8333.1447.0881.9262.2
Upgrade
Other Operating Activities
-4.43-7.17-4.65-5.624.57
Upgrade
Change in Accounts Payable
-2.34-3.231.460.670.09
Upgrade
Change in Unearned Revenue
----84.65-10.51
Upgrade
Change in Other Net Operating Assets
-7.560.111.961.9714.43
Upgrade
Operating Cash Flow
-150.02-162.39-163.69-169.56-126.25
Upgrade
Capital Expenditures
-0.78-0.46-2.69-24.28-65.5
Upgrade
Sale of Property, Plant & Equipment
0.29----
Upgrade
Cash Acquisitions
-41.2-31.35---
Upgrade
Investment in Securities
95.79154.23186.7312.74-56.07
Upgrade
Investing Cash Flow
54.1122.42184.05-11.54-121.57
Upgrade
Issuance of Common Stock
50.411.42.211.1401.24
Upgrade
Repurchase of Common Stock
-0-0.08-0.46-0.46-
Upgrade
Financing Cash Flow
50.411.331.7410.64401.24
Upgrade
Net Cash Flow
-45.52-38.6422.1-170.46153.42
Upgrade
Free Cash Flow
-150.8-162.86-166.38-193.83-191.75
Upgrade
Free Cash Flow Margin
-418900.00%-266980.33%-127984.62%-228.89%-1800.50%
Upgrade
Free Cash Flow Per Share
-8.82-12.46-13.26-15.69-28.22
Upgrade
Levered Free Cash Flow
-81.47-67.56-90.36-53.9-129.82
Upgrade
Unlevered Free Cash Flow
-81.47-67.56-90.36-53.9-129.82
Upgrade
Change in Working Capital
-9.89-3.123.42-82.024.01
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.